Business / Finance

RSS

Benson Group listed on 'Europe's 500' top growth companies

Europe's 500, the association of top European growth entrepreneurs met at the European Parliament in Brussels on February 3rd for the European Growth Summit 2011. An integral part of the event, the "Europe's 500" awards ceremony honoured the top-growth-companies in Europe, and released a list of the 200 fastest-growing, job-creating businesses.

10 Feb 2011

Artimplant fourth quarter net revenue decreases to SEK 3.5 million

Net revenue for the fourth quarter amounted to SEK 3.5 million (5.8) and for January-December SEK 18.5 million (24.0).

10 Feb 2011

Growing number of organizations decide not to drop health-care coverage for employees

While most organizations are not waiting for a repeal of health-care reform, many are looking for further guidance on specific provisions of the law before making decisions on their benefits plans, a new poll by the Society for Human Resource Management (SHRM) found.

10 Feb 2011

Private health sector employment share in the US reaches all-time high of 10.7%

Private sector health care employment in the United States reached an all-time high of 10.7 percent of total employment, according to a report released by Altarum Institute's Center for Studying Health Spending.

10 Feb 2011

Gerresheimer 2010 group revenues increase 5.6% to EUR 1024.8m

Gerresheimer AG, one of the leading worldwide suppliers to the pharma and healthcare industry, finished the financial year 2010 with record results. "The financial year 2010 was very successful for us. Our know-how and products are very much in demand from international pharma customers. Our shareholders should participate in this success.

10 Feb 2011

Healthline Networks, MedHelp expand strategic partnership

Healthline Networks, the leading provider of intelligent health information services, and MedHelp, the world's largest health social network and the leading provider of online and mobile health applications, today announced an expansion of their strategic partnership, naming Healthline as the exclusive third-party representative for custom content programs for selected pharmaceutical advertisers on MedHelp.

10 Feb 2011

BG Medicine underwriters exercise over-allotment option in full

BG Medicine today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.

10 Feb 2011

OraSure registers $3.5 million net loss for full year 2010

OraSure Technologies, Inc., a market leader in oral fluid diagnostics, today announced revenues of $75.0 million and $18.8 million for the year and quarter ended December 31, 2010, respectively. This compares to revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009.

10 Feb 2011

Cephalon to acquire Alba Therapeutics

Cephalon, Inc. and Alba Therapeutics Corporation, a privately held biopharmaceutical company, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all of Alba's assets relating to larazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.

10 Feb 2011

Evotec signs definitive agreement to acquire all shares in Kinaxo

Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

9 Feb 2011

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Zogenix, Inc. today announced that it has received the 2011 Drug Delivery Partnerships™ ("DDP") Innovation Award in the Industry Achievement category for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System.

9 Feb 2011

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

A.P. Pharma provides update on response to APF530 Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its progress toward responding to the Complete Response Letter for APF530 that the Company received from the U.S. Food and Drug Administration (FDA) in March 2010.

9 Feb 2011

MedRisk creates Risk Information and Business Intelligence unit

MedRisk, Inc., the workers' compensation industry leader in specialty managed care services, has announced the creation of its Risk Information and Business Intelligence (RIBI) unit. RIBI's first initiative is to roll out a new reporting platform featuring state-of-the-art graphics and outcomes analytics.

9 Feb 2011

Tibet Pharmaceuticals launches new corporate website

Tibet Pharmaceuticals, Inc., an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announces the launch of a new corporate website.

9 Feb 2011

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.

9 Feb 2011

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

Prestige Brands Holdings, Inc. today announced results for the third quarter and nine months of fiscal year 2011, which ended on December 31, 2010. Following the close of the quarter, the Company completed the previously announced acquisition of the Dramamine® Brand in the U.S. from McNeil-PPC, Inc.

9 Feb 2011

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Sartorius, a leading international laboratory and process equipment provider, successfully closed the year 2010. Sales revenue and earnings substantially surpassed the year-earlier figures. Financial guidance for the Group, which was raised during the course of 2010, was met and even exceeded for some targets.

From Sartorius 9 Feb 2011